TY - JOUR
T1 - Community engagement and clinical trial diversity
T2 - Navigating barriers and co-designing solutions—A report from the “Health Equity through Diversity” seminar series
AU - Reopell, Luiza
AU - Nolan, Timiya S.
AU - Gray, Darrell M.
AU - Williams, Amaris
AU - Brewer, La Princess C.
AU - Bryant, Ashley Leak
AU - Wilson, Gerren
AU - Williams, Emily
AU - Jones, Clarence
AU - McKoy, Alicia
AU - Grever, Jeff
AU - Soliman, Adam
AU - Baez, Jna
AU - Nawaz, Saira
AU - Walker, Daniel M.
AU - Metlock, Faith
AU - Zappe, Lauren
AU - Gregory, John
AU - Joseph, Joshua J.
N1 - Funding Information:
Luiza Reopell was supported through a NIH National Institute of Diabetes and Digestive and Kidney Diseases Administrative Supplement to Diversify the NIDDK Clinical Trial Workforce K23 DK117041-03S1 (JJJ) and by the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program Award ID#76236 (JJJ).
Publisher Copyright:
Copyright: © 2023 Reopell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/2
Y1 - 2023/2
N2 - Introduction In recent years, there has been increasing awareness of the lack of diversity among clinical trial participants. Equitable representation is key when testing novel therapeutic and non-therapeutic interventions to ensure safety and efficacy across populations. Unfortunately, in the United States (US), racial and ethnic minority populations continue to be underrepresented in clinical trials compared to their White counterparts. Methods Two webinars in a four-part series, titled “Health Equity through Diversity,” were held to discuss solutions for advancing health equity through diversifying clinical trials and addressing medical mistrust in communities. Each webinar was 1.5 hours long, beginning with panelist discussions followed by breakout rooms where moderators led discussions related to health equity and scribes recorded each room’s conversations. The diverse groups of panelists included community members, civic representatives, clinician-scientists, and biopharmaceutical representatives. Scribe notes from discussions were collected and thematically analyzed to uncover the central themes.
AB - Introduction In recent years, there has been increasing awareness of the lack of diversity among clinical trial participants. Equitable representation is key when testing novel therapeutic and non-therapeutic interventions to ensure safety and efficacy across populations. Unfortunately, in the United States (US), racial and ethnic minority populations continue to be underrepresented in clinical trials compared to their White counterparts. Methods Two webinars in a four-part series, titled “Health Equity through Diversity,” were held to discuss solutions for advancing health equity through diversifying clinical trials and addressing medical mistrust in communities. Each webinar was 1.5 hours long, beginning with panelist discussions followed by breakout rooms where moderators led discussions related to health equity and scribes recorded each room’s conversations. The diverse groups of panelists included community members, civic representatives, clinician-scientists, and biopharmaceutical representatives. Scribe notes from discussions were collected and thematically analyzed to uncover the central themes.
UR - http://www.scopus.com/inward/record.url?scp=85148287233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85148287233&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0281940
DO - 10.1371/journal.pone.0281940
M3 - Article
C2 - 36795792
AN - SCOPUS:85148287233
SN - 1932-6203
VL - 18
JO - PLoS One
JF - PLoS One
IS - 2 February
M1 - e0281940
ER -